MedTrace Logo

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

NCT06277752 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-22

No results posted yet for this study

Summary

A Phase I study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of IBI128 after multidosing in Chinese health subjects.

Conditions

  • Gout Arthritis

Interventions

DRUG

dose-5 group

IBI128 300mg po. QD(Quaque Die)

DRUG

dose-1 group

IBI128 25mg po. QD(Quaque Die)

DRUG

dose-2 group

IBI128 50mg po. QD(Quaque Die)

DRUG

dose-4 group

IBI128 200mg po. QD(Quaque Die)

DRUG

dose-3 group

IBI128 100mg po. QD(Quaque Die)

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2024-03-16
Completion
2024-03-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277752 on ClinicalTrials.gov